Soleo Health named partner for new drug
By HME News Staff
Updated 9:24 AM CDT, Tue May 7, 2024
FRISCO, Texas – Soleo Health has been named a limited distribution specialty pharmacy partner to dispense RYPLAZIM manufactured by Kedrion Biopharma. RYPLAZIM is the first and only U.S. Food & Drug Administration-approved treatment for supporting the approximately 500 people in the U.S. affected by plasminogen deficiency type 1 (PLGD-1). "We take pride in being among the few selected specialty pharmacy providers administering RYPLAZIM to PLGD-1 patients,” said Drew Walk, CEO of Soleo Health. “Complex conditions like PLGD-1 require our clinical excellence and extensive knowledge to ensure patients receive appropriate access to treatment while simplifying their complex care. We are thankful for our relationship with Kedrion and the opportunity to make a significant difference in these patients’ lives.” Considered an ultra-rare disease, PLGD-1 leads to reduced plasminogen activity levels in the body, often resulting in fibrinous lesions on various organs. Approximately 81% of patients develop lesions on one or both eyes as their primary symptom; however, lesions can develop throughout the body, potentially on all organs with mucous membranes. Patients with PLGD-1 may require lifelong treatment. Soleo Health has 26 pharmacy locations with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission. Additionally, the Company operates more than 30 infusion centers throughout the U.S.
Comments